{"schema_version":"secwatch.filing_event.v1","accession":"0001326732-26-000014","form_type":"8-K","ticker":"XNCR","cik":"0001326732","company_name":"Xencor Inc","filed_at":"2026-02-25T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.813031+00:00","generated_at":"2026-05-16T00:09:45.474476+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Xencor Q4 net loss narrows to $6.7M; XmAb819 dose expansion advances; Xtend royalty upside $100-120M","bullets":["Q4 revenue $28.2M (down 47% YoY), full year $125.6M (up 14%). Net loss $6.7M ($0.09/sh) vs $45.6M prior-year Q4.","Cash $610.8M at Dec 31, 2025; expects $400-430M at end 2026, funding operations through 2028.","XmAb819 (ENPP3 x CD3) dose expansion open in CRC, NSCLC, pRCC; plan to present data 2H26 for recommended Ph3 dose, pivotal start 2027.","Xtend U.S. patent to Dec 2028; expects $100-120M aggregate royalty above OMERS cap from Ultomiris sales."],"urls":{"canonical":"https://secwatch.observer/filing/0001326732-26-000014","json":"https://secwatch.observer/filing/0001326732-26-000014.json","markdown":"https://secwatch.observer/filing/0001326732-26-000014.md","text":"https://secwatch.observer/filing/0001326732-26-000014.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1326732/000132673226000014/0001326732-26-000014-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1326732/000132673226000014/xncr-20260225.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T00:09:45.474476+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}